Nouscom reveals promising results for lynch syndrome immunotherapy

NOUS-209 shows potential to intercept cancer in its early stages

Nouscom has announced full safety and immunogenicity results from its phase 1b/2 trial of NOUS-209, an off-the-shelf immunotherapy for Lynch Syndrome (LS). These findings will be shared in an oral presentation at the American Academy of Cancer Research (AACR) Annual Meeting in Chicago this April.

The trial, which enrolled 45 participants with LS, assessed NOUS-209 as a potential cancer interception strategy. Results confirmed the therapy’s safety, with no serious treatment-related adverse events.

It demonstrated impressive neoantigen-specific T cell responses in all evaluable participants, inducing durable and robust immune responses against frameshift peptide neoantigens.

Lynch Syndrome is caused by inherited mutations in DNA repair genes, significantly elevating lifetime cancer risks. Current disease management relies on frequent screenings or preventative surgeries, which have their limitations. NOUS-209 aims to address these challenges by training the immune system to detect and eliminate precancerous and cancerous cells.

NOUS-209 targets mismatch repair-deficient and microsatellite instability-associated tumours, using unique frameshift peptide neoantigens to stimulate the immune system. Its broad potential application across MSI tumour types underscores its promise as a breakthrough therapy.

Following positive US FDA meetings, Nouscom plans to advance NOUS-209 to a phase 2/3 trial, which could pave the way for registration. The therapy’s ability to efficiently stimulate immune responses offers hope for individuals with LS, transforming cancer prevention strategies.